Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

The Directory and digital round-up

SOPHiA Genetics acquires IBS, Kyomed becomes KYomed INNOV and launches ePRO, Medtronic unveil diabetes app

Hello and welcome to The Directory news round-up where we capture the latest stories within the digital healthcare, branding, PR, creative and advertising space.

IBSSOPHiA GENETICS acquires French tech company IBS

Health-tech company SOPHiA GENETICS has acquired French-based technology group Interactive Biosoftware (IBS), along with its widely adopted Alamut programme.

Alamut is currently deployed in over 450 hospitals and SOPHiA GENETICS has said the software is “highly complementary” to the group’s offering.

As per terms of the deal, IBS’ expertise and teams will join SOPHiA GENETICS’ workforce with the united goal to accelerate the global adoption of data-driven medicines.

Jurgi Camblong, chief executive officer and co-founder of SOPHiA GENETICS, said: “The addition of Alamut marks a big step in our aim to help clinicians better diagnose patients equally.

“With a community of now over 900 teaching hospitals using our technologies we are in a unique position to connect clinicians and enable them to share knowledge.

KYomed INNOVKyomed re-brands and launches new app

Kyomed, a French company offering services in connected healthcare, autonomy and personalised medicine, marks its fourth anniversary, rebranding to KYomed INNOV.

Alongside the name change, the company is upping the ante in the digital space, launching the development of its own digital tools.

It will initially roll out its fully customisable app electronic Patient Reported Outcomes – also known as ePRO – allowing patients to self-report symptoms for biomedical research.

The tool falls in line with the French health authority Haute Autoritee de Santé’s good practice guide for connected health applications and devices, meaning that clients will be able to integrate collected data into clinical studies.

Daniel Laune, president of KYomed INNOV, said: “We are reinventing ourselves, using our expertise to launch global projects and to develop innovative solutions which offer a real benefit to our clients.”

iPro2Medtronic unveil glucose support app

Medical technology group Medtronic has updated and re-launched iPro2 myLog app, offering a way for clinics to import diabetes patients’ logged data during their glucose monitoring evaluation.

The app now includes a meal logging option called FoodPrint, where patients’ meals are graded based on their body’s unique glucose reaction.

Medtronic says this new feature makes it “easy” for patients to understand the link between meals and glucose variability via a generated report.

The new app is powered by artificial intelligence and personalised nutrition analysis platform Nutrino, and chief executive Yael Glassman said that they are “confident that the addition of FoodPrint into the iPro2 professional CGM evaluation will have a positive impact for individuals living with type 2 diabetes”.

Article by
Gemma Jones

19th June 2018

From: Research, Marketing, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

OPEN Health Graduates and the XP Support Group
During our graduate induction period in September 2018, we were asked to find a charity that could benefit from the expertise of the OPEN Health practices. We made the decision...
Alexander Devine Website has gone live!
As part of the OPEN Health CSR programme one of the charities we support is Alexander Devine. They are a local Children's Hospice based in Maidenhead who provide a truly...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...